Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

NCT02052739 is registered in ClinicalTrials.gov with Supernus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02052739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02052739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
Lead sponsor
Supernus Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 21, 2014
Completion date
May 3, 2015
Enrollment
25 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

super-refractory status epilepticus